Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

As a population, we are all learning how to operate and function during this current global COVID-19 pandemic. But what does this mean for businesses in the pharmaceutical industry who are trying to navigate the landscape during this time?

Can the industry really claim it's 'business as usual'?

Everyone is claiming ‘business as usual’ but is this really the case when there are restrictions on global travel and social distancing? Tony O'Sullivan, Chief Commercial Officer at ChargePoint Technology says: "In a word, yes."

O'Sullivan explains that although delays in receiving APIs and raw materials appear to be one of the biggest current challenges, the industry is proving it has solid and working business continuity plans in place.

"Even with the loss of many big industry events, the industry is being creative and finding new ways to speak to and meet with those we would normally be networking with face to face via virtual meetings," says O'Sullivan.

He also notes that companies are also applying this approach to their products — they are conducting virtual demos from living rooms and home offices all over the world.

O'Sullivan adds: "Headquarters are operating within government guidelines, but this isn’t stopping the operational aspect of these businesses, it’s merely providing a new dynamic in which to work safely but still efficiently."

As well as drug developers and manufacturers, those supplying vital containment and sterility assurance equipment used in pharmaceutical manufacturing environments play an important role in the supply chain. Those that are best set up to support their customers remotely will thrive in the current situation.

“Operational efficiency and fulfilling customers' requirements are both inherently part of all of ChargePoint’s processes and these will be particularly important as we strive to continue to overcome all hurdles brought on by this extraordinary situation," says O'Sullivan.

Furthermore, he notes the importance of the industry coming together at this time to help fight and slow this pandemic, whether that’s through direct industry partnerships or via local and regional networks.

"There’s no denying that the Coronavirus pandemic is a very serious concern to everyone in the pharmaceutical industry. It is no surprise that virtually overnight, many vaccine and drug developers pivoted, shifting development resources to focus on pharmaceutical-based solutions to prevent, control and treat the disease. As they make progress, manufacturers will need to step in to help to commercialize their products and bring them to market, concludes O'Sullivan.

Read More

Related news

HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more 
AbbVie completes Allergan acquisition

AbbVie completes Allergan acquisition

11 May 2020

Creates biopharmaceutical company with leadership positions in immunology, hematologic oncology, neuroscience, and Allergan aesthetics.

Read more